Insights

Strategic partnerships BC3 Technologies has recently expanded distribution through Acme United Corporation and entering a retail collaboration with Army & Air Force Exchange Service (AAFES), presenting a channel growth opportunity to engage military, government, and educational buyers through established networks.

Product expansion Recent launches of SEAL and SEAL Hemostatic Wound Spray, with first retail availability and professional deployments, indicate growing product adoption and opportunities to upsell to EMS, police, and first responder procurement programs.

Public sector fit With a professional version adopted by police departments and EMS across the United States, there is a clear pathway to pursue additional contracts, grants, and wholesale agreements within public safety and defense sectors.

Scale and capacity Current revenue visibility in the low-to-mid single digits and recent funding of several million suggest capacity for larger or multi-year orders; target opportunities include bulk procurement via military/Air Force, hospital networks, and national distributors.

Competitive positioning BC3T’s high-hemostatic activity, stability, and cost advantages in chitosan-based aerosols offer a differentiator to pursue value-based selling with procurement teams focusing on performance, safety, and total cost of ownership for wound care solutions.

Similar companies to BC3 Technologies

BC3 Technologies Tech Stack

BC3 Technologies uses 8 technology products and services including iCIMS, Squarespace, Google Workspace, and more. Explore BC3 Technologies's tech stack below.

BC3 Technologies's Email Address Formats

BC3 Technologies uses at least 1 email format:
BC3 Technologies Email FormatsExamplePercentage
First@bc3tech.comJohn@bc3tech.com
100%

Frequently Asked Questions

What is BC3 Technologies's official website and social media links?

Minus sign iconPlus sign icon
BC3 Technologies's official website is bc3tech.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does BC3 Technologies generate?

Minus sign iconPlus sign icon
As of September 2026, BC3 Technologies's annual revenue is estimated to be $1M - $10M.

What is BC3 Technologies's SIC code and NAICS code?

Minus sign iconPlus sign icon
BC3 Technologies's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BC3 Technologies have currently?

Minus sign iconPlus sign icon
As of September 2026, BC3 Technologies has approximately 8 employees across 1 continents, including North America. Key team members include Chief Strategy Officer (cso): K. C. and President: W. G. Explore BC3 Technologies's employee directory with LeadIQ.

What industry does BC3 Technologies belong to?

Minus sign iconPlus sign icon
BC3 Technologies operates in the Biotechnology Research industry.

What technology does BC3 Technologies use?

Minus sign iconPlus sign icon
BC3 Technologies's tech stack includes iCIMS, Squarespace, Google Workspace, Font Awesome, HubSpot, Google Search Console, Piwik PRO Core and Apache HTTP Server.

What is BC3 Technologies's email format?

Minus sign iconPlus sign icon
BC3 Technologies's email format typically follows the pattern of First@bc3tech.com. Find more BC3 Technologies email formats with LeadIQ.

How much funding has BC3 Technologies raised to date?

Minus sign iconPlus sign icon
As of September 2026, BC3 Technologies has raised $3.8M in funding. The last funding round occurred on Nov 26, 2025 for $150K.

When was BC3 Technologies founded?

Minus sign iconPlus sign icon
BC3 Technologies was founded in 2018.
BC3 Technologies logo

BC3 Technologies

Biotechnology ResearchMaryland, United States2-10 Employees

BC3 Technologies, based in Baltimore, Maryland, is a small biotechnology research firm focused on antihemorrhagic products for medical, military, and consumer markets. The company employs a proprietary chitosan-based aerosol that can be applied to wounds and supports rapid clotting, with performance and cost comparable to existing products. The technology is described as stable and versatile, aiming for a broad range of applications.

Its customers include healthcare providers, emergency responders, and other users seeking effective wound control. In September 2023, BC3 Technologies released a professional version of SEAL, its hemostatic wound spray, which has been adopted by police departments and EMS across the United States. In September 2024, the company announced a distribution partnership with First Aid Only to expand SEAL's reach.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
2-10

Section iconFunding & Financials

  • $3.8M

    BC3 Technologies has raised a total of $3.8M of funding over 3 rounds. Their latest funding round was raised on Nov 26, 2025 in the amount of $150K as a Venture Round.

  • $1M - $10M

    BC3 Technologies's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.